Laroprovstat lowered LDL on rosuvastatin over 28 days in a phase 1 study. Safety was the primary objective; cardiovascular benefit and long-term safety remain unproven.
Author: Hormone Insight Editorial Team
Read More
In the REAL8 SGA substudy, weekly somapacitan was noninferior to both daily GH doses at one year and superior only to the lower-dose comparator.
A pharmacokinetic crossover study and a four-week post hoc CAH subgroup analysis support biochemical effects, not established long-term clinical or safety benefits.
A 90-person trial found less weight regain with a specific pasteurised Akkermansia preparation over 24 weeks. Findings cannot be generalised to other supplements.
LIBerate-HoFH found variable LDL responses and did not establish lerodalcibep noninferiority to evolocumab at its prespecified margin. Read the PICO appraisal.
A 13-person crossover trial found higher ketone concentrations with dapagliflozin, without changing the primary GLP-1 endpoint. This is not a safety endorsement.
REAL8 found greater first-year height velocity with weekly somapacitan than daily GH in Noonan syndrome. Adult height and long-term safety remain separate questions.
BaxHTN found placebo-corrected systolic reductions of 8.7 and 9.8 mm Hg at 12 weeks. Review potassium events and why this differs from Bax24.
CARE-PWS did not meet its primary high-dose endpoints. Lower-dose hyperphagia findings were nominal secondary results, not a confirmatory efficacy success.
HISTORI tested semaglutide in schizophrenia with prediabetes and obesity. Review HbA1c and weight effects, gastrointestinal harms and psychiatric limitations.